68Ga-PSMA PET/CT用于高危前列腺癌原发淋巴结及远处转移NM分期
该研究纳入691例连续新诊断、活检证实、未经治疗的高危前列腺癌患者,行68Ga-PSMA PET/CT原发分期,并与传统风险分层参数及根治性前列腺切除加盆腔淋巴结清扫组织病理比较。结果显示35.3%患者存在进展期疾病,ISUP分级是进展期疾病的优越预测因子,ISUP 2级与3级间进展期疾病频率有显著差异,未检出的淋巴结转移为PSMA阴性或微转移。
要点
- 高危前列腺癌患者中35.3%(244/691)在诊断时存在进展期疾病(N1/M1)。
- 淋巴结转移(N1/M1a)检出率为31.4%(217/691),骨转移(M1b)为16.8%(116/691)。
- 68Ga-PSMA PET/CT检测淋巴结转移的灵敏度为30.6%,特异度为96.5%。
核心结论
- 在该高危前列腺癌队列中,约三分之一患者诊断时存在进展期疾病,ISUP分级是诊断时进展期疾病的优越预测因子。
- ISUP 2级与3级之间进展期疾病频率有显著差异,支持Gleason评分7的细分。
- 比较不同cT2分期时,进展期疾病风险无显著差异;未检出的淋巴结转移为PSMA阴性或微转移。
研究设计与样本
- 研究纳入691例连续新诊断、活检证实、未经治疗、D'Amico高危前列腺癌患者,行68Ga-PSMA PET/CT原发分期。
- 比较PSMA SUVmax及转移发现与前列腺特异性抗原水平、国际泌尿病理学会(ISUP)分级及临床分期等传统风险分层参数。
- 在行根治性前列腺切除加盆腔淋巴结清扫的患者中,将68Ga-PSMA PET/CT发现与组织学发现比较,未检出的淋巴结转移行免疫组化PSMA染色。
主要发现
- 进展期疾病(N1/M1)见于35.3%(244/691)患者,并与前列腺特异性抗原水平、ISUP分级及临床分期升高相关。
- 淋巴结转移(N1/M1a)检出率为31.4%(217/691),骨转移(M1b)为16.8%(116/691)。
- ISUP 2级与3级患者进展期疾病频率分别为10.8%(11/102)与37.1%(33/89)。
- cT2a、cT2b、cT2c肿瘤进展期疾病风险几乎相等,分别为24.2%、27.9%、22.4%。
- SUVmax与活检ISUP分级呈弱相关(ρ=0.21;P<0.001),与前列腺切除后ISUP分级呈中等相关(ρ=0.38;P<0.001)。
关键数值与推荐
- 进展期疾病(N1/M1)频率:35.3%(244/691)。
- 淋巴结转移(N1/M1a)频率:31.4%(217/691);骨转移(M1b)频率:16.8%(116/691)。
- ISUP 2级与3级进展期疾病频率:10.8%(11/102) vs 37.1%(33/89)。
- SUVmax与活检ISUP分级相关系数ρ=0.21(P<0.001),与前列腺切除后ISUP分级ρ=0.38(P<0.001)。
- 68Ga-PSMA PET/CT检测淋巴结转移:灵敏度30.6%、特异度96.5%、阳性预测值68.8%、阴性预测值84.5%、准确率83.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With the largest high-risk prostate cancer (PCa) cohort to date undergoing 68Ga-prostate-specific membrane antigen (PSMA) PET/CT primary staging, we aimed to, first, characterize the metastatic spread of PCa in relation to tumor 68Ga-PSMA uptake and the D'Amico classification and, second, compare 68Ga-PSMA PET/CT findings with radical prostatectomy and pelvic lymph node dissection (PLND) histopathology findings. Methods: The study included 691 consecutive newly diagnosed, biopsy-proven, treatment-naïve, D'Amico high-risk PCa patients primary-staged by 68Ga-PSMA PET/CT. PSMA SUVmax and metastatic findings were compared with prostate-specific antigen level, International Society of Urological Pathology (ISUP) grade, and clinical stage as traditional risk stratification parameters. Moreover, 68Ga-PSMA PET/CT findings were compared with histology findings in radical prostatectomy patients undergoing PLND. Undetected lymph node metastases (LNMs) underwent immunohistochemical PSMA staining. Results: Advanced disease (N1/M1) was observed in 35.3% of patients (244/691) and was associated with increasing prostate-specific antigen level, ISUP grade, and clinical stage. LNMs (N1/M1a) were detected in 31.4% (217/691) and bone metastases (M1b) in 16.8% (116/691). Advanced disease frequencies in patients with ISUP grades 2 and 3 were 10.8% (11/102) and 37.1% (33/89), respectively. Risk of advanced disease for cT2a, cT2b, and cT2c tumors was almost equal (24.2%, 27.9%, and 22.4%, respectively). We observed a weak correlation between SUVmax and biopsy ISUP grade (ρ = 0.21; P < 0.001) and a modest correlation between SUVmax and postprostatectomy ISUP grade (ρ = 0.38; P < 0.001). Sensitivity, specificity, positive and negative predictive value, and accuracy for LNM detection on 68Ga-PSMA PET/CT in the PLND cohort were 30.6%, 96.5%, 68.8%, 84.5%, and 83.1%, respectively. Undetected LNMs either were micrometastases located in the lymph node border or were without PSMA expression. Conclusion: In this high-risk PCa cohort, we identified advanced disease in about one third at diagnosis. ISUP grade was the superior predictor for advanced disease at diagnosis. We found a significant difference in frequency of advanced disease between ISUP grades 2 and 3, as supports the Gleason score 7 subdivision. Interestingly, we observed no significant differences in risk of advanced disease when comparing the different cT2 stages. The undetected LNMs were either PSMA-negative or micrometastases.
引用
- Klingenberg S, Jochumsen MR, Ulhøi BP, et al. 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer. J Nucl Med. 2020. PMID: 32444374. doi:10.2967/jnumed.120.245605
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。